How to Cite
Abstract
There was studied material of primary tumors from 140 patients with adenocarcinoma of the colon to determine the expression of thymidylate synthetase (TS), thymidine phosphorylase (TP), dihydropyrimidine dehydrogenase, ERCC-1, beta-tubulin III, topoisomerase-II-alpha, Ki-67. Comparison of the clinical picture and the results of immunohistochemistry were performed to 104 patients with adenocarcinoma of the colon who had undergone chemotherapy by FOLFOX, de Gramont, FOLFIRI schemes. The objective response in the presence of TP expression and absence of TS was 39%, the reverse combination (TS expression and no TP) was 13%. Other markers showed no correlation with the occurrence of disease progression and response rate.References
Arienti C., Tesei A., Verdecchia G.M. et al. Role of conventional chemosensitivity test and tissue biomarker expression in predicting response to treatment of peritoneal carcinomatosis from colon cancer // Clin. Colorectal Cancer. - 2013. - Vol. 12. - P. 122-127.
Belac-Lovasic I., Petkovi M., Ferrari A.M. Evaluation of adjuvant chemotherapy in patients with colorectal cancer in Primorsko-Goranska and Istarska County--a twenty years retrospective study // Coll. Antropol. - 2011. - Vol. 35. - P. 111-114.
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer: International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators // Lancet. - 1995. - Vol. 345. - P. 939-943.
Gray R.G., Quirke P., Handley K. et al. Validation study of a quantitative multigene reverse transcriptase-polymerase chain reaction assay for assessment of recurrence risk in patients with stage II colon cancer // J. Clin. Oncol. - 2011. - Vol. 29. - P. 4611-4619.
Karlberg M., Ohrling K., Edler D. et al. Prognostic and predictive value of thymidylate synthase expression in primary colorectal cancer // Anticancer Res. - 2010. - Vol. 30, № 2. - P. 645-651.
Lassmann S., Hennig M., Rosenberg R. et al. Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up // Int. J. Colorectal Dis. - 2006. - Vol. 21. - P. 238-247.
Lindskog E.B., Wettergren Y., Odin E. et al. Thymidine phosphorylase gene expression in stage III colorectal cancer // Clin. Med. Insights. Oncol. - 2012. - Vol. 6. - P. 347-353.
O’Connel M.J., Mailliard J.A., Kahn M.J. et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer // J. Clin. Oncol. - 1997. - Vol. 15. - P. 246-250.
Ojima E., Inoue Y., Watanabe H. et al. The optimal schedule for 5-fluorouracil radiosensitization in colon cancer cell lines // Oncol Rep. - 2006. - Vol. 16. - P. 1085-1091.
Uchida P.V., Danenberg K.D., Danenberg J.L. Thymidylate synthase, dihydropyrimidine dehydrogenase, ERCC1, and thymidine phosphorylase gene expression in primary and metastatic gastrointestinal adenocarcinoma tissue in patients treated on a phase I trial of Oxaliplatin and capecitabine // BMC Cancer. - 2008. - Vol. 23. - P. 1121-1130.
Yu X.Q., Deng C.S., Zhu Y.Q., Cheng F.Z. Effects of expression of thymidine phosphorylase induced by gamma-interferon on regulation of antineoplastic activity of fluorouracil on colonic cancer // Zhonghua Yi. Xue. Za. Zhi. - 2005. - Vol. 85. - P. 568-570.
Weiss J.M., Schumacher A.J., Allen G.O. et al. Chemotherapy for Stage II Right-Sided and Left-Sided Colon Cancer: Analysis of SEER-Medicare Data [Электронный ресурс] // Ann. Surg. Oncol. - 2014. Режим доступа: http://www.ncbi.nlm.nih.gov/pubmed/24643898.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...